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18 Oral Presentationsthe inability of KGF treatment to increase peripheral regulatory T-
cell numbers. In summary, pre-transplant administration of KGF
can accelerate thymic recovery post allo-HSCT and that the in-
creased export of newly generated T-cells can blunt peripheral ex-
pansion of post-thymic T-cells. However, this thymus-dependent
effect of KGF is insufficient to further ameliorate cGVHD. Never-
theless, the results suggest a potentially important role of KGF in
immune reconstitution and modulation of cGVHD post-allo-
HSCT.42
IN VIVO EXPANSION OF CD41FOXP31 REGULATORY T CELLS MAY
CONTRIBUTE TO CONTROL OF ACUTE GVHD AFTER HLA-MISMATCHED
ALLOANERGIZED HSCT
Davies, J.1, Yuk, D.1, Brennan, L.2, Nadler, L.1, Guinan, E.2. 1Dana
Farber Cancer Institute, Boston, MA; 2Dana Farber Cancer Institute,
Boston, MA.
Many strategies have been explored to selectively remove allor-
eactive donor T cells to prevent Graft-versus-Host Disease
(GvHD) without impairing immune reconstitution after hemato-
poietic stem cell transplantation (HSCT). An alternative approach
is allostimulation of donor T cells with costimulatory blockade
(CSB) rendering allospecific cells anergized (hyporesponsive to sub-
sequent alloantigenic challenge). Murine and human data suggest
that induction of alloanergy involves cell-mediated suppression, re-
quiring the presence of CD41CD251 regulatory T cells (Tregs).
We conducted a pilot study of haploidentical alloanergized
HSCT after CSB, and measured reconstitution of Treg by intracel-
lular flow cytometry. 5 patients (pts; 4 acute leukemia, one marrow
failure) underwent cyclophosphamide/TBI-conditioned haploi-
dentical HSCT with cyclosporine and methotrexate GvHD pro-
phylaxis. Donor bone marrow was incubated with irradiated
recipient peripheral blood mononuclear cells and anti-B7.1/2 anti-
bodies for 48 hours to induce alloanergy, washed and infused. All pts
engrafted with very rapid reconstitution of T cell subsets, NK cells
and immunoglobulins. All evaluable patients had a marked relative
increase in peripheral blood CD41FOXP31 cells at D 1 20–60.
CD41FOXP31 cells had a memory Treg phenotype (CD251
CD45RO1CTLA41 CD127Lo) and were predominantly HLA
DR- differentiating them from activated T cells. Despite receiving
high doses of donor T cells (median 1.8 (CD4) and 3.1 (CD8) 
107/kg) and achieving full donor chimerism, only 2 pts developed
acute GvHD, both Grade II, resolving after short courses of corti-
costeroids. All evaluable patients also had an increase in CD41 T
effector (Teff) cells with an activated phenotype
(CD251HLADR1FOXP3-) atD1 30–50. Although the antigenic
specificity of Teff was not determined, cytokine secretion may have
led to reversal of anergy and expansion of alloreactive Teff cells.
The marked in vivo expansion of Treg may represent one mecha-
nism of suppressing alloreactive Teff and achieving immunological
control of acute GvHD without impairing immune reconstitution
in pts receiving HLA-mismatched alloanergized donor T cells.
We are using a modification of this strategy in a clinical trial of de-
layed infusion of escalating doses of alloanergized donor T cells af-
ter CD34-selected haploidentical HSCT, to determine the optimal
dose of alloanergized donor T cells that abrogates acute GvHD
without impairment of immune reconstitution.43
ADMINISTRATION OF rhIL-7 INCREASES TCR REPERTOIRE DIVERSITY
THROUGH PREFERENTIAL EXPANSION OF NAIVE T CELLS
Hakim, F.T.1, Memon, S.A.1, Sportes, C.1, Zhang, H.2, Chua, K.2,
Fry, T.2, Engel, J.3, Buffet, R.3, Morre, M.3, Mackall, C.2,
Gress, R.E.1. 1National Cancer Institute, NIH, Bethesda, MD; 2Na-
tional Cancer Institute, NIH, Bethesda, MD; 3Cytheris Inc., Rockville,
MD.
Interleukin-7 (IL-7) is a multifunctional cytokine with critical
and non-redundant roles in thymopoiesis and peripheral T-cell ho-
meostasis. We previously reported preliminary results of the first
Phase I study of recombinant human IL-7 (rhIL-7), demonstratingthat two weeks of alternate day treatment with rhIL-7 produced
a marked increase in the number of CD41 and CD81 T cells.
This increase was maintained in follow up assays at 6 to 12 weeks
post treatment. Furthermore, rhIL-7 therapy disproportionately in-
creased CD271CD45RA1 naive cells, which represent the most
diverse elements of the mature T cell receptor (TCR) repertoire,
at the expense of CD27-CD45RA1/- effector populations, which
are often oligoclonal. In CD8 T cells, the proportion of naive cells
increased by 8–39% of total cells. Because of the extent of this pop-
ulation shift, we hypothesized that rhIL-7 treatment would lead to
an overall increase in TCR repertoire diversity in CD41 and
CD81 T-cells. We assessed TCR diversity using spectratype anal-
ysis on sorted CD4 and CD8 populations before and one week after
rhIL-7 therapy (day 21) in six subjects. For each patient, we deter-
mined the divergence of spectratypes in 22 BV families fromGauss-
ian-like normal donor standards and then compared the global
diversity of pre and post spectratypes byWilcoxon paired non-para-
metric analysis.Wedetermined that rhIL-7 therapy induced a statis-
tically significant increase (P\ .05) in repertoire diversity in either
the CD41, CD81, or bothT-cell populations in 4 of the 6 patients.
This enhancement in diversity was particularly remarkable in that
three of these donors were over 60 years of age, and a fourth patient
had reduced lymphocyte populations due to recent chemotherapy.
Given the short duration of therapy, the age of the patients and
the very modest change in TREC we observed, we believe this en-
hancement in diversity was due primarily to differential population
expansion, not IL-7 induced thymic output. Consistent with this in-
terpretation, we observed that a higher percentage of naive T cells
than effector T cells remained in cycle (Ki-671) and maintained el-
evated levels of anti-apoptotic Bcl-2 during IL-7 therapy.We there-
fore propose that rhIL-7 has the potential to induce T-cell growth
and enhance repertoire diversity, even in lympho-depleted patients
with limited thymopoietic capacities, by expanding naive T cell
populations.44
THE CD41CD251FOXP31 COMPARTMENT FOLLOWING CONDITION-
ING AND TRANSPLANT: HOST TREG CELLS EXPAND AND COMPRISE
THE PREDOMINANT COMPONENT FOR SEVERAL MONTHS DURING RE-
CONSTITUTION POST-HCT
Bayer, A.L., Jones, M., Urbieta, M., Chirinos, J., Schreiber, T.,
Armas, L., Thomas, M.R., Levy, R.B. University of MiamiMiller School
of Medicine, Miami, FL.
The capacity of CD41CD251Foxp31 (Treg) cells to regulate
adaptive and innate immune responses has led to studies investigat-
ing their use in novel strategies to regulate allogeneic T cell re-
sponses during hematopoietic stem cell transplants (HCT). A
fundamental clinical concern post-HCT is the reconstitution of
the lymphoid compartment, particularlyT cells which can be excep-
tionally delayed. We have previously found that host Treg cells can
regulate resistance to engraftment following HCT, demonstrating
that such cells survive and function at least transiently in recipients.
The present studies investigated the residual host Treg compart-
ment following varying levels of conditioning (3.0 – 14Gy TBI),
and transplant.We found that recipient CD41CD251Foxp31 cells:
1) can survive ablative as well as reduced intensity conditioning, 2)
undergo expansion (BrdU uptake/cell numbers) and 3) contribute
greatly to the Treg compartment for several months post-HCT
during which time donor derived Treg cells gradually arise and
cede this compartment. Within the first 3 weeks post-lethal condi-
tioning and HCT, 95% of the splenic CD41FoxP31 cells are pos-
itive for BrdU, vs. 40% in normal mice. Using Thy1.1 congenic
mice, the vast majority of these cells were found to be resistant
(host) Tregs. Two months post-HCT, almost 30% of the compart-
ment was still of host origin. To assess the functional capacity of the
residual Treg cell compartment, we examined development of auto-
immune disease following transplant of IL-2Rb2/2 BM into synge-
neic recipients. Autoimmune disease was prevented in B6-wt but
not T cell deficient recipients. Interestingly, the failure to transfer
autoimmune disease following IL-2Rb2/2 HCT into B6-CD4-/-
recipients was associated with the presence of a peripheral
CD81FoxP31 population not detected in B6-wt mice. This finding
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latory population may emerge. In total, our observations support
the notion that functioning host Tregs initially occupy a niche in
the transplant recipient permitting lymphopenic expansion and an
extended period of contribution to this compartment. Notably,
this contribution reflected much greater levels than that by other
lymphoid cell populations. Overall, the findings imply that host
Treg cells may be important to consider with respect to eliciting
anti-tumor and vaccination responses in recipients during the early
period post-hematopoietic cell transplantation.45
DEVELOPMENT OF ANTIBODIES TO SELF ANTIGENS K-ALPHA-1 TUBU-
LIN AND COLLAGEN V IN PATIENTS WITH CHRONIC GRAFT VERSUS
HOST DISEASE
Pusic, I.1, Saini, D.2, Pavletic, S.Z.3, Hakim, F.3, Shannon, W.D.1,
Mohanakumar, T.2,4, DiPersio, J.F.1. 1Washington University School
of Medicine, St. Louis, MO; 2Washington University School of Medicine,
St. Louis, MO; 3National Institutes of Health, Bethesda, MD; 4Wash-
ington University School of Medicine, St. Louis, MO.
Background:ChronicGraft vs.HostDisease (cGVHD) is amul-
tisystem alloimmune and autoimmune disorder characterized by
production of antibodies, immune dysregulation and impaired or-
gan function resembling autoimmune diseases. NIH Consensus
Criteria for cGVHD (Filipovich et al, BBMT 11:945, 2005) defines
bronchiolitis obliterans (BO) diagnosed clinically as a distinctive
feature (seen in cGVHDbut insufficient alone to establish the diag-
nosis) and BO diagnosed by lung biopsy as a diagnostic feature of
cGVHD (sufficient to establish the diagnosis). Chronic rejection
following human lung transplantation is strongly associated with
development of alloimmune response to donor mismatched HLA
antigens. Recent studies in our laboratory and others have shown
a strong correlation between development of autoimmunity to self
antigens K-alpha-1 tubulin and collagen V with tissue damage
and immunopathogenesis of chronic rejection characterized by
BO. In this study, we analyzed the presence of antibodies to self-an-
tigens K-alpha-1 tubulin and collagen V in patients with cGVHD.
Methods: Serum samples from patients with cGVHD were ana-
lyzed for antibodies which bind to human recombinant purified
K-alpha-1 tubulin (1 mcg/ml) and collagen V using ELISA assays.
Analysis of variance was used to compare the means of different
groups with p\0.05 as an indicator of strong association. Results:
Study includes 21 patients with cGVHDdeveloping after allogeneic
transplantation for hematological malignancies and 10 normal con-
trols. 11 patients with cGVHD had lung involvement by NIH Cri-
teria with minimal lung score of 2. Levels of K-alpha-1 tubulin
antibodies were higher in patients with lung cGVHD when com-
pared to patients without lung involvement or normal controls (p
5 0.027). Levels of Collagen V antibodies were higher in patients
with lung cGVHD when compared to normal controls (p 5
0.025) but not when compared to patients without cGVHD of the
lung. 64% of patients with lung involvement by cGVHD developed
antibodies to both antigens and 82% had antibodies to at least one.
Conclusion: In this preliminary analysis development of antibodies
to K-alpha-1 tubulin and to collagen V appears to be highly associ-
ated with cGVHD and the highest titer autoantibodies are seen in
those patients with lung involvement. Studies are underway to de-
fine the kinetics of these antibodies after transplantation and their
incidence and titers in allogeneic stem cell recipients without clin-
ical signs of cGVHD.46
ANDROGEN WITHDRAWAL MODULATES THYMOPOIESIS BY INDUCING
THYMIC EPITHELIAL CELL PROLIFERATION AND INCREASING PRECUR-
SOR NICHE
Williams, K.M., Lucas, P.J., Bare, C.V., Wang, J., Chu, Y.-W.,
Gress, R.E. National Institutes of Health/National Cancer Institute,
Bethesda, MD.Impaired thymopoiesis contributes to immune deficiency follow-
ing allogeneic stem cell transplantation. Emerging clinical literature
suggests that graft-versus-host disease may be exacerbated and
graft-versus-leukemia effect compromised in the setting of thymic
insufficiency. Data have demonstrated that the thymus is damaged
following the transplant preparative regimen, with a depletion of
UEA1 thymic epithelial cells. We show that castration of male
mice results in thymic renewal, as demonstrated by increased thy-
mocyte number, intrathymic T cell receptor excision circles, and
the number of early thymic progenitors (ETP: Lin- CD25- c-kit
hi CD44 hi) as early as eight days post-castration. These observa-
tions suggested a mechanism of enhanced thymopoieis that occurs
through increased immigration of thymocyte precursors. Studies
with adoptively transferred congenic marrow progenitors confirm
that enhanced ETP immigration is an early event following andro-
gen withdrawal. Data also demonstrate a significant increase in
UEA1 thymic epithelial cell proliferation by BRDU1 incorpora-
tion in the initial time frame following castration, implicating thy-
mic epithelial cell proliferation in this thymic expansion, and
suggesting that there may be an increase in thymic niche regulating
ETP uptake.We have further identified an increase in a stromal de-
rived protein important for ETP uptake by Western blot in total
thymus lysates consistent with a mechanism of an increased ETP
niche. Preliminary data also suggest that the mRNA encoding this
protein is increased in sorted thymic epithelial subsets, with the
greatest increase in the UEA1 medullary TEC cells, implicating
these medullary epithelial cells in ETP entry. Taken together, we
show that androgen withdrawal leads to UEA1medullary cell pro-
liferation with augmented ETP niche and entry. Thus, we identify
ETP uptake as a critical and dynamically controlled point of thymic
regulation.LATE EFFECTS/QUALITY OF LIFE47
PROSPECTIVE NEUROCOGNITIVE FUNCTION AND RISK FACTORS AT 5
YEARS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
(HCT) FOR HEMATOLOGIC MALIGNANCIES, COMPARED WITH CON-
TROLS AT 5 YEARS
Syrjala, K.L.1,2, Artherholt, S.B.1, Kurland, B.F.1, Langer, S.L.1,2,
Martin, P.J.1,2, Roth-Roemer, S.3, Abrams, J.R.1, Elrod, J.B.2,
Dikmen, S.2. 1Fred Hutchinson Cancer Research Center, Seattle, WA;
2University of Washington, Seattle, WA; 3Arizona Medical Psychology,
Scottsdale, AZ.
Investigators have documented significant cognitive decline after
high dose treatment followed by allogeneic HCT. We have deter-
mined that partial recovery occurs by 1 year, but deficits remain
in verbal capacity and motor skills. Our current aims were to deter-
mine the extent of long-term cognitive dysfunction, and risk factors
for deficits at 5 years.We hypothesized improvement between 1 and
5 years, and that risk factors would include type of treatment before
transplant, and duration of immunosuppressant medications. A to-
tal of 142 adults completed neuropsychological tests for verbal
memory (Hopkins Verbal Learning Test; HVLT), verbal fluency
(Controlled Oral Word Association Test; COWAT), information
processing (Digit Symbol and Trail Making B; Trails B) and motor
dexterity and speed (Grooved Pegboard), among other tests. Survi-
vors were re-tested after 80 days, and 1 and 5 years post-transplant.
A neuropsychologist traveled to test each of N5 66 5 year survivors
and case-matched controls in person. Generalized estimating equa-
tions indicated significant changes over time frompretransplant to 5
years in all tests except memory (P\ .0001; memory P 5 .17). Be-
tween 1 and 5 years, verbal fluency continued to improve (P5 .001),
as did information processing (P\ .01); but motor dexterity and,
memory did not (P . .65), remaining below controls (P\ .0001
motor dexterity, P 5 .060 verbal memory). Table 1 indicates the
percent impaired (t score # 40) at 5 years. The only identified
risk factor for poorer verbal memory at 5 years was history of intra-
thecal chemotherapy or cranial irradiation (95% Confidence Inter-
val (CI) 0.71, 15.13, P 5 .03). Risk factors for impaired motor
dexterity and speed at 5 years included immunosuppression longer
